突触囊泡内分细胞缺陷是帕金森病和患有勒维体痴呆症的GBA相关认知功能障碍的基础
D J Vidyadhara1,2,3,4, David Bäckström1,2,5, Risha Chakraborty1,2
1Departments of Neurology, Yale University, CT, USA.
Research square
|January 7, 2025
概括
葡萄糖脑蛋白酶 (GBA) 突变会导致帕金森病 (PD) 和患有勒维体痴呆症 (DLB) 的认知缺陷,因为它会损害独立于α-synuclein的突触囊膜内细胞酶.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- GBA基因是帕金森病 (PD) 和患有勒维体痴呆症 (DLB) 的主要危险因素.
- 这些神经退行性疾病的特点是认知缺陷和α-synuclein病理.
研究的目的:
- 研究GBA突变在认知衰退中的作用.
- 在小鼠模型中探索GBA突变,α-synuclein和神经退行之间的相互作用.
主要方法:
- 使用了Gbe突变,SNCA转基因和双突变小鼠.
- 在小鼠皮层上进行了单核RNA测序,免疫组织化学和电子显微镜.
主要成果:
- GBA突变小鼠表现出早期的认知缺陷,但没有运动缺陷或α-synuclein病理.
- 转基因SNCA小鼠表现出运动缺陷而没有认知异常.
- 双重突变的小鼠表现出认知衰退和加剧的运动缺陷,皮质-α-synuclein增加.
- 在Gba突变和双突变小鼠的激发神经元中发现了突触囊内分细胞缺陷,这些缺陷与调节突触囊循环的下调基因有关.
结论:
- GBA突变通过涉及突触囊泡内分细胞功能障碍的α-synuclein独立机制导致认知缺陷.
- 在PD和DLB的背景下,GBA突变加剧了α-synuclein聚合和运动缺陷.
关键词:
认知功能障碍 认知功能障碍痴呆症与利维体的痴呆症.在GBA中,GBA是GBA.莱维体痴呆症 (Lewy体痴呆症) 是一种疾病.帕金森病是帕金森氏症的一种疾病.帕金森氏症与痴呆症相关的疾病.这是SNCA的SNCA.这就是 snRNA-seqq.突触性可塑性 突触性可塑性突触囊泡内细胞结合症 (synaptic vesicle endocytosis) 是一种突触囊泡内细胞结合症.α-synuclein 是一种同核蛋白.α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies,即α-synucleinopathies.相关概念视频
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Parkinson's Disease: Overview
472
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
472
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Parkinson's Disease: Treatment
215
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
215
Dementia
94
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
94
Fusion of Secretory Vesicles with the Plasma Membrane
10.9K
Proteins and neurotransmitters in secretory vesicles can be released from a cell upon vesicle docking, priming, and fusion with the plasma membrane. Vesicles are docked and primed in preparation for the quick exocytosis of their contents in response to a stimulus. The fusion process is mainly carried out by a SNAP Receptor or SNARE complex, consisting of synaptobrevin, syntaxin-1, and SNAP-25.
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
10.9K


